Evaluation of PSA-age volume score in predicting prostate cancer in Chinese population

Wu, Yishuo; Wu, Xiaoqing; Zhang, Ning; Jiang, Guangliang; Yu, Yang; Tong, Shijun; Jiang, Haowen; Mao, Shanhua; Na, Rong; Ding, Qiang

doi:10.4103/aja.aja_81_17

Cited by 15 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the detection rate was 25.3% among a Chinese cohort from Shanghai with a PSA level of 4.0–10.0 ng ml −1 and 36.5% among those with PSA level of 10.0–20.0 ng ml −1 22. Another study from Shanghai reported a detection rate of 26.2% in patients with PSA level of 2.0–20.0 ng ml −1 29. The detection rate in a Chinese cohort from Guangzhou with PSA level of 2.5–20.0 ng ml −1 was only 25.6% 30.…”

Section: Discussionmentioning

confidence: 98%

Comparison of diagnostic efficacy between transrectal and transperineal prostate biopsy: A propensity score-matched study

et al. 2019

View full text Add to dashboard Cite

This study compared the diagnostic efficacy of transrectal ultrasound (TRUS)-guided prostate biopsy (TRBx) and transperineal prostate biopsy (TPBx) in patients with suspected prostate cancer (PCa). We enrolled 2962 men who underwent transrectal (n = 1216) or transperineal (n = 1746) systematic 12-core prostate biopsy. Clinical data including age, prostate-specific antigen (PSA) level, and prostate volume (PV) were recorded. To minimize confounding, we performed propensity score-matching analysis. We measured and compared PCa detection rates between TRBx and TPBx, which were stratified by clinical characteristics and Gleason scores. The effects of clinical characteristics on PCa detection rate were assessed by logistic regression. For all patients, TPBx detected a higher proportion of clinically significant PCa (P < 0.001). Logistic regression analyses illustrated that PV had a smaller impact on PCa detection rate of TPBx compared with TRBx. Propensity score-matching analysis showed that the detection rates in TRBx were higher than those in TPBx for patients aged ≥ 80 years (80.4% vs 56.5%, P = 0.004) and with PSA level 20.1–100.0 ng ml−1 (80.8% vs 69.1%, P = 0.040). In conclusion, TPBx was associated with a higher detection rate of clinically significant PCa than TRBx was; however, because of the high detection rate at certain ages and PSA levels, biopsy approaches should be optimized according to patents' clinical characteristics.

show abstract

Section: Discussionmentioning

confidence: 98%

Comparison of diagnostic efficacy between transrectal and transperineal prostate biopsy: A propensity score-matched study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Furthermore, the prostate volume, based on MRI, could improve the effectiveness of tPSA for predicting PCa. [22,23] PSA–AV, incorporating age, prostate volume and serum tPSA, is a parameter to predict PCa, which was introduced by Patel et al [10] Wu YS et al [11] had tested the PSA–AV performance in predicting PCa and proved that it was an effective variable in diagnosing PCa, especially in young patients and those with small prostate volumes.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, the role of PSA–AV in the Chinese population is proved preliminarily, especially in younger patients. [11] Therefore, this study investigates the ability of PSA–AV to detect PCa in the gray zone with PI-RADS v2 score 3 or serum tPSA 4 to 10 ng/mL.…”

Section: Introductionmentioning

confidence: 99%

Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen–age volume

Lu¹,

Zhang²,

Chen³

et al. 2019

Medicine

View full text Add to dashboard Cite

To improve the detection of prostate cancer (PCa) by combining the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) and prostate-specific antigen–age volume (PSA–AV), especially among those in gray zone with PI-RADS v2 score 3 or serum total prostate-specific antigen (tPSA) 4 to 10 ng/mL. The 357 patients were enrolled in this study. The PI-RADS v2 scoring system was used to represent characteristics on multiparametric magnetic resonance imaging (mpMRI). PI-RADS v2 score 3 or tPSA 4 to 10 ng/mL were defined as the gray zone in detecting PCa. The formula equates to the patient age multiplied by the prostate volume, which is divided by the tPSA level. Univariate and multivariate analyses were done to ascertain significant predictors of prostate cancer. In all, 174 (48.7%) were benign prostatic hyperplasia, 183 (51.3%) had PCa. The results showed that PI-RADS v2, tPSA, and PSA–AV were significant independent predictors of prostate cancer. PI-RADS v2 score ≥4 could detect PCa with rate of 82.1%. Serum tPSA ≥10 ng/mL could detect PCa with rate of 66.2%, PSA density (PSAD) ≥0.15 ng/mL/cc with rate of 62.8%, and PSA–AV ≤250 with rate of 83.5%. Combining with PSA–AV ≤250, patients those with tPSA 4 to 10 ng/mL could improve the detection from 36.0% up to 81%, those with PI-RADS v2 score 3 from 28.6% up to 60.0%. PI-RADS v2 and PSA–AV are faithful variables for detecting PCa. And for patients, those in gray zones of PI-RADS v2 and tPSA, PSA–AV can improve detection rate of PCa.

show abstract

“…Due to this phenomenon, the PSA-AV score was developed from the trio of tPSA, age and prostate volume. Studies have shown that PSA-AV score has better diagnostic performance than tPSA (Wu et al, 2018). damage exists equally in all stages of progression, independent of risk.…”

Section: Ta B L E 3 Diagnostic Performances Of Parameters Distinguishing Pca From Bphmentioning

confidence: 99%

Total thiol can contribute to differentiating prostate cancer from BPH: Prostate Thiol Index as a new player

Arpa

Şen²,

Eren

et al. 2021

Andrologia

View full text Add to dashboard Cite

To assess the distinctiveness of serum native thiol (NT), total thiol (TT) and disulfide (SS) levels in PCa patients, we created a new parameter, prostate thiol index (PTI)[tPSA (TTxPVxAge) −1/2 ]. We determined the performance of the PTI on PCa diagnosis. A total of 107 male patients (PCa:65; BPH:42) who were separated according to their Gleason scores, ISUP grades and EAU risk groups and 20 healthy subjects were included. The performances of the tests were determined. The PCa and BPH groups had lower NT and TT levels and higher SS levels than the control group. PCa patients had higher PTI, tPSA, fPSA, PSAD levels, lower fPSA%, PV and PSA-AV levels than BPH patients. TT, PTI, tPSA, fPSA, fPSA%, PSA-AV, PSAD and PV had significant diagnostic performances. PTI had the highest AUC value and accuracy, PSA-AV had the highest specificity, and fPSA had the lowest sensitivity.

show abstract

Evaluation of PSA-age volume score in predicting prostate cancer in Chinese population

Cited by 15 publications

References 35 publications

Comparison of diagnostic efficacy between transrectal and transperineal prostate biopsy: A propensity score-matched study

Comparison of diagnostic efficacy between transrectal and transperineal prostate biopsy: A propensity score-matched study

Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen–age volume

Total thiol can contribute to differentiating prostate cancer from BPH: Prostate Thiol Index as a new player

Contact Info

Product

Resources

About